At Our Ocean Conference, Global Fishing Watch welcomes international partnerships to enhance ocean management

Key collaborations will bolster fisheries governance through greater transparency, data-sharing and policy reform

ATHENS, Greece, April 17, 2024 (GLOBE NEWSWIRE) — Global Fishing Watch, an international nonprofit organization dedicated to advancing ocean governance through transparency of human activity at sea, has announced three pioneering collaborations with Greece, Panama and the West African Sub-Regional Fisheries Commission (SRFC) in a bid to harness technology and data-driven solutions for enhanced transparency, improved fisheries management and greater ocean sustainability.

The partnerships, unveiled at the 9th Our Ocean Conference held in Athens, Greece, will leverage open data to combat illegal, unreported and unregulated (IUU) fishing, promote sustainable fisheries management and enable marine protection through deepened engagement with governmental bodies spanning three continents. In addition, they will provide Global Fishing Watch the opportunity to highlight transparency as a critical marine management tool and advance policy reforms regarding the adoption of vessel tracking methods like automatic identification systems (AIS) and vessel monitoring systems (VMS), as well as regional data sharing practices.

Today’s announcements mark a milestone in our collaborative efforts to mobilize open data and technology in the fight against illegal fishing and toward improved global fisheries management,” said Tony Long, chief executive officer of Global Fishing Watch. “More importantly, our expanding network of partnerships shows that governments and multilateral institutions are increasingly recognizing the role Global Fishing Watch can play in achieving better and more transparent ocean governance.”

Collaborative partnerships, political will and open data can drive tangible impact and help deliver lasting results for a sustainable ocean future for all,” Mr. Long added. 

Leveraging Technology for Ocean Action

Presented at an official conference side event co-hosted by Greece, the Athanasios C. Laskaridis Charitable Foundation and Global Fishing Watch, the partnership with Greece commits authorities to utilizing Global Fishing Watch’s platform, which provides visualizations and analysis of fishing activity, for critical support in bolstering the country’s marine protection efforts.

Greece commits to establishing a scientific monitoring and surveillance system for all its marine protected areas that will be supported with advanced monitoring techniques and digital tools, such as remote sensing and automatic communication with sea vessels,” Dr. Petros Varelidis, Secretary-General for Natural Environment and Waters of the Hellenic Ministry of Environment and Energy, confirmed. “The support of Global Fishing Watch and the Athanasios C. Laskaridis Charitable Foundation will enable us to monitor fishing activity in near real-time.”

A ‘significant step forward’ against IUU fishing

The Our Ocean Conference also welcomed a new partnership between Global Fishing Watch and the seven West African SRFC Member States comprising Cabo Verde, Gambia, Guinea, Guinea- Bissau, Mauritania, Senegal and Sierra Leone. Through the new three-year agreement with SRFC, Global Fishing Watch will support Member States with analysis and generated insights to inform targeted monitoring, control and surveillance (MCS) actions, bolstering countries’ abilities to manage activity in their waters and safeguard livelihoods and regional economic and environmental ecosystems.

The 5,500 kilometer coastline of West Africa is home to some of the most diverse fisheries in the world and maritime activity plays a key role across the region. Indeed, fisheries and aquaculture directly contribute US$24 billion to the African economy, with the demand for fish expected to increase by 30 percent by 2030. Inadequate monitoring and enforcement, however, have led to rampant IUU fishing, with nearly 40 percent of fish caught illegally, resulting in substantial economic losses and environmental degradation.

The collaboration with Global Fishing Watch represents a significant step forward in the fight against illegal fishing in West Africa,” said Dr. Khallahi Brahim, Permanent Secretary of the Sub-Regional Fisheries Commission. “By joining forces, Global Fishing Watch and the SRFC can help transform fisheries governance, protect marine resources and secure the livelihoods of millions of people dependent on the fishing industry.”

The new partnership will work to ensure that SRFC Member States are fully equipped for better cooperation, monitoring and compliance, and also help establish cross-cutting initiatives with key stakeholders in ocean governance. The collaboration will pave the way for policy reforms and seek to establish AIS usage and data sharing as central pillars of SRFC Member States’ governance practices. It will also support government agencies in developing and retaining capacity to harness data and technology to strengthen management, including MCS, enforcement and marine protection.

Charting a new era of ocean governance

Global Fishing Watch’s activity on the margins of the Our Ocean Conference also saw the renewal of an ongoing collaboration with the Government of Panama, first launched in 2019, aimed at building an improved, collaborative framework for data-sharing and policy development.

The updated agreement reflects a deepened relationship between the two parties and a growing commitment to fisheries transparency. Supplementing the VMS data of its vast international fleet, which has been visible on the Global Fishing Watch map since October 2019, Panama will now share vessel data from its list of international licenses, including fishing licenses, areas of operation and information related to fishing support vessels. Over the next five years, Global Fishing Watch will also provide technical and data-driven assessments for the Aquatic Resources Authority of Panama to help inform national policies and regulations related to fisheries management.

We are pleased to announce the renewal of the memorandum of understanding with Global Fishing Watch in our tireless fight against illegal, unreported and unregulated fishing,” said Hamed Tuñón, General Administrator, Aquatic Resources Authority of Panama. “Our strengthened alliance reflects the continued commitment of both parties to protecting our oceans and preserving their biodiversity. Together, we will continue to use innovative technology and collaborative strategies to ensure the sustainability of our valuable marine resources.”

Now, more than ever, the global community must rally behind landmark initiatives to protect our ocean, combat harmful practices, and achieve ambitious conservation targets such as safeguarding at least 30 percent of the ocean by 2030,” Mr. Long concluded.Achieving these critical commitments will be virtually impossible without Global Fishing Watch’s innovative ocean monitoring technology and expertise.”

Attachments

Kimberly Vosburgh
Global Fishing Watch
5185902979
KIMBERLY@GLOBALFISHINGWATCH.ORG

GlobeNewswire Distribution ID 9090876

TokenEx and IXOPAY to Merge, Enabling Merchants to Optimize the Use of Multiple Payment Processors

Payments Optimization Platform for Global Commerce Delivers Omnichannel Tokenization, Payments Orchestration, and Card Lifecycle Management

TokenEx_IXOPAY_Merge
TokenEx_IXOPAY_Merge

TokenEx and IXOPAY merged on April 17, 2024 to become IXOPAY, a TokenEx Company.

TULSA, Okla. and VIENNA, Austria, April 17, 2024 (GLOBE NEWSWIRE) — TokenEx, the leading cloud tokenization provider, and IXOPAY, the leading independent payments orchestration platform, today are announcing their definitive agreement to merge, creating a new leader in global payments optimization. The combined company will be called IXOPAY, a TokenEx Company, and Marc Olesen will lead the combined organization as CEO. Customers will benefit from a comprehensive platform that enables increased authorization rates and decreased interchange fees for merchants, along with PCI-certified secure payment data.

This merger brings together the strengths of TokenEx’s expertise in tokenization of payment data, and IXOPAY’s world-class payments orchestration, including transaction routing & reconciliation capabilities.

“This merger marks a significant milestone in the payments industry,” said Marc Olesen, CEO. “By joining forces, IXOPAY, a TokenEx Company is uniquely positioned to help merchants develop a payments strategy that optimizes the use of multiple payment processors to enhance both top and bottom-line results.”

TokenEx’s merger with IXOPAY marks a pivotal step in the transformation of the payments industry toward supporting a multi-processor approach to payments, delivering a complete unified payments platform that includes:

  • Omnichannel Tokenization — Universal Tokens enable merchants to use one payment token for in-person and online transactions and all payment processors. This eliminates storing payment data in multiple systems, reduces system complexity, and provides unified customer data.
  • Payments Orchestration — This highly scalable payments orchestration platform for merchants delivers intelligent routing, cascading, and state-of-the-art risk management functions as well as centralized reconciliation and settlements along with plugin-based integration of over 200 acquirers, Alternative Payment Methods, and payment service providers.
  • Card Lifecycle Management — A complete set of capabilities for managing the entire transaction lifecycle at scale, including updating expired cards, leveraging the efficiency of network tokens, streamlined routing with BIN Lookup, and authenticating transactions with 3D Secure.

“By merging with TokenEx we not only bring together our unique capabilities to become the most comprehensive payments platform for global merchants, but we can also utilize the expertise of the TokenEx team to provide first-class service to our primarily European customers in the U.S. market,” said Rene Siegl, Founder and Executive Chairman of IXOPAY. “For merchants who value the competitive advantage that comes with treating payments as strategic, IXOPAY, a TokenEx Company will ultimately deliver a complete omnichannel payments optimization platform with best-in-class tokenization and intelligent transaction routing — giving merchants unprecedented control over their revenue and the competitive edge to thrive in global commerce.” Both Rene Siegl, Founder and Nathalie Siegl, CEO will remain with IXOPAY, a TokenEx Company as executives.

About TokenEx

TokenEx is a cloud tokenization and payment optimization provider committed to helping organizations safely and compliantly process and transmit sensitive data. Its industry-leading solution for data protection can secure and desensitize any structured data element to reduce risk, streamline operations, and enable critical business processes.

About IXOPAY

IXOPAY is a best-of-breed payment orchestration platform offering flexible and independent global payment processing options. IXOPAY provides smart transaction routing with cascading, state-of-the-art risk and fraud management, fully automated reconciliation and settlements processing, comprehensive reporting and access to hundreds of acquirers, payment service providers and alternative payment methods.

Media Contact:

Nicholas Mueller

nmueller@tokenex.com

510-289-2001

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/27147864-91b0-4683-aa19-d4c4690d323a

GlobeNewswire Distribution ID 9089826

DALI Alliance Launch Test and Certification Specifications for DALI+

DALI Alliance Launches DALI +

The DALI Alliance, recognized as the international authority in lighting technology standardization, has unveiled much-anticipated certification details for its wireless specification: DALI+ over Thread.

LONDON, April 16, 2024 (GLOBE NEWSWIRE) — The DALI Alliance, recognized as the international authority in lighting technology standardization, has unveiled much-anticipated certification details for its wireless specification: DALI+ over Thread.

As lighting specifications increasingly seek smarter, sustainable, and interoperable solutions, DALI+ emerges as a crucial enabler of standardized wireless or IP-based lighting systems. The alliance’s collaboration with partners such as Thread Group has resulted in the integration of enhanced security and encryption solutions, ensuring the integrity and confidentiality of data transmission within DALI+ networks.

Key features of DALI+ with Thread include:

  • Wireless Mesh Network: Thread creates an Internet Protocol version 6 (IPv6) based wireless mesh network. Off-the-shelf Thread border routers can also be used to connect multiple Thread networks through IP technologies, such as Ethernet or Wi-Fi, allowing a highly scalable lighting control system.
  • Extended Addressing: In addition to the standard 64 control gear and 64 control device addresses, DALI+ with Thread IPv6 routing allows almost unlimited addressing capability. The usual DALI broadcast, group and short-addressing methods are included together with IP unicast and multicast capability.
  • Interoperability: DALI+ certification includes all the benefits of the existing DALI-2 and D4i certification programs with extensive testing, independent verification, and listing of every certified product in a publicly searchable product database to ensure a high level of product interoperability. Furthermore, DALI+ bridge devices will allow DALI-2 wired devices or systems to connect with and operate with the products in a DALI+ wireless system.
  • Device Support: DALI+ supports a wide array of control devices, including occupancy sensors, light sensors, switches, sliders, rotaries, and pushbuttons. Control gear support currently includes LED drivers with the three optional data parts: luminaire data, power and energy, and diagnostics data.

Paul Drosihn, General Manager of the DALI Alliance, expressed enthusiasm about the launch, stating, “This represents a significant advancement in DALI-enabled technology. Our members and users will experience the benefits of enhanced wireless interoperability and strengthened sustainability credentials.” Drosihn continues, “Moreover, this milestone underscores our steadfast commitment to driving innovation and nurturing eco-conscious solutions within the industry. By leveraging the potential of DALI technology, we are not only revolutionizing lighting controls but also laying the groundwork for a more sustainable future for generations to come.”

DALI Alliance launches DALI+ (1)

Commenting on the collaboration, Klaus Waechter, VP Commercial Buildings at Thread, said, “We are proud to collaborate with the DALI Alliance in utilizing Thread technology in the DALI+ specification. This partnership underscores our commitment to advancing wireless connectivity and interoperability for commercial grade markets and the lighting industry in general.”

For more information, please contact press@parrotprandmarketing.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/cab88b27-8652-41d6-a8b9-23f872dd416c

GlobeNewswire Distribution ID 1000934974

Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer

Dr. Khan, formerly the Chief Data Science Officer and Global Head of Strategy and Portfolio, Innovative Medicine R&D at Johnson & Johnson (J&J), will also join Recursion’s Board of Directors

Photo of Najat Khan, Ph.D.

Najat Khan, Ph.D.

SALT LAKE CITY, April 16, 2024 (GLOBE NEWSWIRE) — Recursion (Nasdaq: RXRX), a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery and development, announced Najat Khan, PhD, will be its Chief R&D Officer and Chief Commercial Officer. Dr. Khan will lead Recursion’s research and development, and build its emerging commercial capabilities. She has also been appointed to Recursion’s Board of Directors.

“Najat brings a unique blend of leadership in biological, chemical, and medical sciences, data science, and business,” said Chris Gibson, Co-Founder and CEO of Recursion. “More importantly, she has a vision and passion for transforming drug discovery and development that complements ours and she has a strong sense of urgency to accelerate the industry’s future. We are excited to welcome her as a Recursionaut to drive our portfolio pipeline, as well as create commercial strategies as we continue to industrialize the creation of high impact medicines.”

Dr. Khan has deep expertise in the pharmaceutical and healthcare industry, spanning biological, chemical, and medical science, computational and data science, and general business leadership, with a focus on driving substantial patient and business value. As the Chief Data Science Officer and Global Head of Strategy and Portfolio Organization, for Innovative Medicine R&D at Johnson & Johnson, Najat played an integral role with the senior leadership team in building an industry-leading pipeline that delivered multiple transformational medicines. She has been a pioneer in driving the impact of data science/AI at scale while establishing a top-tier diverse data science team, underpinning her commitment to innovation and excellence at the intersection of healthcare and technology. Dr. Khan co-chaired Johnson & Johnson’s Data Science Council, where she has played a key leadership role in driving the adoption of data science across the company to achieve business impact and deploy best practices for data use, AI, ethics, as well talent recruitment and development.

“My mission and focus has been to harness the power of science, data, and AI to revolutionize the way we discover, develop, and deliver transformative medicines for patients”, said Dr. Khan, “This seamlessly aligns with Recursion’s goal to pioneer the burgeoning TechBio sector and decode biology and chemistry to radically improve lives. I believe their approach represents the future of our industry, and sets Recursion to be at the forefront to deliver on this vision. I’m thrilled to be part of Recursion’s board and leadership team, embarking on this vital mission together.”

Dr. Khan serves as a board member for Alliance for Artificial Intelligence in Healthcare and is a Steering Committee member of the White House’s Moonshot CancerX program to enhance outcomes for cancer patients. Najat is the founder and co-chair of the Data Science in Industry Roundtable (DISRUPT) – a cross industry forum dedicated to driving impact through Data Science. She is an alumna of University of Pennsylvania with a doctorate in Organic Chemistry leveraging experimental and computational approaches, has an undergraduate degree in Computational Chemistry and a minor in Business / Economics from Colgate University, and is published in various high-impact journals.

“We are pleased to welcome Najat to the board to guide the strategic vision of Recursion,” said Dean Li, Co-Founder and Board Member of Recursion and President, Merck Research Laboratories, “Najat shares our outlook on how the industry needs to evolve, and I believe her insight will be highly valuable as we enter the era of AI enabled drug discovery and development.”

About Recursion
Recursion is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological, chemical and patient-centric datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale — up to millions of wet lab experiments weekly — and massive computational scale — owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology, chemistry and patient-centric data to advance the future of medicine.

Recursion is headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah life sciences industry collective. Recursion also has offices in Toronto, Montreal and the San Francisco Bay Area. Learn more at www.Recursion.com, or connect on X (formerly Twitter) and LinkedIn.

Media Contact
Media@Recursion.com

Investor Contact
Investor@Recursion.com

Forward-Looking Statements
This document contains information that includes or is based upon “forward-looking statements” within the meaning of the Securities Litigation Reform Act of 1995, including, without limitation, all statements that are not historical facts. Forward-looking statements may or may not include identifying words such as “plan,” “will,” “expect,” “anticipate,” “intend,” “believe,” “potential,” “continue,” and similar terms. These statements are subject to known or unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements, including but not limited to: challenges inherent in pharmaceutical research and development, including the timing and results of preclinical and clinical programs, where the risk of failure is high and failure can occur at any stage prior to or after regulatory approval due to lack of sufficient efficacy, safety considerations, or other factors; our ability to leverage and enhance our drug discovery platform; our ability to obtain financing for development activities and other corporate purposes; the success of our collaboration activities; our ability to obtain regulatory approval of, and ultimately commercialize, drug candidates; our ability to obtain, maintain, and enforce intellectual property protections; cyberattacks or other disruptions to our technology systems; our ability to attract, motivate, and retain key employees and manage our growth; inflation and other macroeconomic issues; and other risks and uncertainties such as those described under the heading “Risk Factors” in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K. All forward-looking statements are based on management’s current estimates, projections, and assumptions, and Recursion undertakes no obligation to correct or update any such statements, whether as a result of new information, future developments, or otherwise, except to the extent required by applicable law.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/21f011ab-bada-4c3e-a55f-d8eabecf35ad

GlobeNewswire Distribution ID 9090097

Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer

Dr. Khan, formerly the Chief Data Science Officer and Global Head of Strategy and Portfolio, Innovative Medicine R&D at Johnson & Johnson (J&J), will also join Recursion’s Board of Directors

Photo of Najat Khan, Ph.D.

Najat Khan, Ph.D.

SALT LAKE CITY, April 16, 2024 (GLOBE NEWSWIRE) — Recursion (Nasdaq: RXRX), a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery and development, announced Najat Khan, PhD, will be its Chief R&D Officer and Chief Commercial Officer. Dr. Khan will lead Recursion’s research and development, and build its emerging commercial capabilities. She has also been appointed to Recursion’s Board of Directors.

“Najat brings a unique blend of leadership in biological, chemical, and medical sciences, data science, and business,” said Chris Gibson, Co-Founder and CEO of Recursion. “More importantly, she has a vision and passion for transforming drug discovery and development that complements ours and she has a strong sense of urgency to accelerate the industry’s future. We are excited to welcome her as a Recursionaut to drive our portfolio pipeline, as well as create commercial strategies as we continue to industrialize the creation of high impact medicines.”

Dr. Khan has deep expertise in the pharmaceutical and healthcare industry, spanning biological, chemical, and medical science, computational and data science, and general business leadership, with a focus on driving substantial patient and business value. As the Chief Data Science Officer and Global Head of Strategy and Portfolio Organization, for Innovative Medicine R&D at Johnson & Johnson, Najat played an integral role with the senior leadership team in building an industry-leading pipeline that delivered multiple transformational medicines. She has been a pioneer in driving the impact of data science/AI at scale while establishing a top-tier diverse data science team, underpinning her commitment to innovation and excellence at the intersection of healthcare and technology. Dr. Khan co-chaired Johnson & Johnson’s Data Science Council, where she has played a key leadership role in driving the adoption of data science across the company to achieve business impact and deploy best practices for data use, AI, ethics, as well talent recruitment and development.

“My mission and focus has been to harness the power of science, data, and AI to revolutionize the way we discover, develop, and deliver transformative medicines for patients”, said Dr. Khan, “This seamlessly aligns with Recursion’s goal to pioneer the burgeoning TechBio sector and decode biology and chemistry to radically improve lives. I believe their approach represents the future of our industry, and sets Recursion to be at the forefront to deliver on this vision. I’m thrilled to be part of Recursion’s board and leadership team, embarking on this vital mission together.”

Dr. Khan serves as a board member for Alliance for Artificial Intelligence in Healthcare and is a Steering Committee member of the White House’s Moonshot CancerX program to enhance outcomes for cancer patients. Najat is the founder and co-chair of the Data Science in Industry Roundtable (DISRUPT) – a cross industry forum dedicated to driving impact through Data Science. She is an alumna of University of Pennsylvania with a doctorate in Organic Chemistry leveraging experimental and computational approaches, has an undergraduate degree in Computational Chemistry and a minor in Business / Economics from Colgate University, and is published in various high-impact journals.

“We are pleased to welcome Najat to the board to guide the strategic vision of Recursion,” said Dean Li, Co-Founder and Board Member of Recursion and President, Merck Research Laboratories, “Najat shares our outlook on how the industry needs to evolve, and I believe her insight will be highly valuable as we enter the era of AI enabled drug discovery and development.”

About Recursion
Recursion is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological, chemical and patient-centric datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale — up to millions of wet lab experiments weekly — and massive computational scale — owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology, chemistry and patient-centric data to advance the future of medicine.

Recursion is headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah life sciences industry collective. Recursion also has offices in Toronto, Montreal and the San Francisco Bay Area. Learn more at www.Recursion.com, or connect on X (formerly Twitter) and LinkedIn.

Media Contact
Media@Recursion.com

Investor Contact
Investor@Recursion.com

Forward-Looking Statements
This document contains information that includes or is based upon “forward-looking statements” within the meaning of the Securities Litigation Reform Act of 1995, including, without limitation, all statements that are not historical facts. Forward-looking statements may or may not include identifying words such as “plan,” “will,” “expect,” “anticipate,” “intend,” “believe,” “potential,” “continue,” and similar terms. These statements are subject to known or unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements, including but not limited to: challenges inherent in pharmaceutical research and development, including the timing and results of preclinical and clinical programs, where the risk of failure is high and failure can occur at any stage prior to or after regulatory approval due to lack of sufficient efficacy, safety considerations, or other factors; our ability to leverage and enhance our drug discovery platform; our ability to obtain financing for development activities and other corporate purposes; the success of our collaboration activities; our ability to obtain regulatory approval of, and ultimately commercialize, drug candidates; our ability to obtain, maintain, and enforce intellectual property protections; cyberattacks or other disruptions to our technology systems; our ability to attract, motivate, and retain key employees and manage our growth; inflation and other macroeconomic issues; and other risks and uncertainties such as those described under the heading “Risk Factors” in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K. All forward-looking statements are based on management’s current estimates, projections, and assumptions, and Recursion undertakes no obligation to correct or update any such statements, whether as a result of new information, future developments, or otherwise, except to the extent required by applicable law.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/21f011ab-bada-4c3e-a55f-d8eabecf35ad

GlobeNewswire Distribution ID 9090097

Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer

Dr. Khan, formerly the Chief Data Science Officer and Global Head of Strategy and Portfolio, Innovative Medicine R&D at Johnson & Johnson (J&J), will also join Recursion’s Board of Directors

Photo of Najat Khan, Ph.D.

Najat Khan, Ph.D.

SALT LAKE CITY, April 16, 2024 (GLOBE NEWSWIRE) — Recursion (Nasdaq: RXRX), a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery and development, announced Najat Khan, PhD, will be its Chief R&D Officer and Chief Commercial Officer. Dr. Khan will lead Recursion’s research and development, and build its emerging commercial capabilities. She has also been appointed to Recursion’s Board of Directors.

“Najat brings a unique blend of leadership in biological, chemical, and medical sciences, data science, and business,” said Chris Gibson, Co-Founder and CEO of Recursion. “More importantly, she has a vision and passion for transforming drug discovery and development that complements ours and she has a strong sense of urgency to accelerate the industry’s future. We are excited to welcome her as a Recursionaut to drive our portfolio pipeline, as well as create commercial strategies as we continue to industrialize the creation of high impact medicines.”

Dr. Khan has deep expertise in the pharmaceutical and healthcare industry, spanning biological, chemical, and medical science, computational and data science, and general business leadership, with a focus on driving substantial patient and business value. As the Chief Data Science Officer and Global Head of Strategy and Portfolio Organization, for Innovative Medicine R&D at Johnson & Johnson, Najat played an integral role with the senior leadership team in building an industry-leading pipeline that delivered multiple transformational medicines. She has been a pioneer in driving the impact of data science/AI at scale while establishing a top-tier diverse data science team, underpinning her commitment to innovation and excellence at the intersection of healthcare and technology. Dr. Khan co-chaired Johnson & Johnson’s Data Science Council, where she has played a key leadership role in driving the adoption of data science across the company to achieve business impact and deploy best practices for data use, AI, ethics, as well talent recruitment and development.

“My mission and focus has been to harness the power of science, data, and AI to revolutionize the way we discover, develop, and deliver transformative medicines for patients”, said Dr. Khan, “This seamlessly aligns with Recursion’s goal to pioneer the burgeoning TechBio sector and decode biology and chemistry to radically improve lives. I believe their approach represents the future of our industry, and sets Recursion to be at the forefront to deliver on this vision. I’m thrilled to be part of Recursion’s board and leadership team, embarking on this vital mission together.”

Dr. Khan serves as a board member for Alliance for Artificial Intelligence in Healthcare and is a Steering Committee member of the White House’s Moonshot CancerX program to enhance outcomes for cancer patients. Najat is the founder and co-chair of the Data Science in Industry Roundtable (DISRUPT) – a cross industry forum dedicated to driving impact through Data Science. She is an alumna of University of Pennsylvania with a doctorate in Organic Chemistry leveraging experimental and computational approaches, has an undergraduate degree in Computational Chemistry and a minor in Business / Economics from Colgate University, and is published in various high-impact journals.

“We are pleased to welcome Najat to the board to guide the strategic vision of Recursion,” said Dean Li, Co-Founder and Board Member of Recursion and President, Merck Research Laboratories, “Najat shares our outlook on how the industry needs to evolve, and I believe her insight will be highly valuable as we enter the era of AI enabled drug discovery and development.”

About Recursion
Recursion is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological, chemical and patient-centric datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale — up to millions of wet lab experiments weekly — and massive computational scale — owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology, chemistry and patient-centric data to advance the future of medicine.

Recursion is headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah life sciences industry collective. Recursion also has offices in Toronto, Montreal and the San Francisco Bay Area. Learn more at www.Recursion.com, or connect on X (formerly Twitter) and LinkedIn.

Media Contact
Media@Recursion.com

Investor Contact
Investor@Recursion.com

Forward-Looking Statements
This document contains information that includes or is based upon “forward-looking statements” within the meaning of the Securities Litigation Reform Act of 1995, including, without limitation, all statements that are not historical facts. Forward-looking statements may or may not include identifying words such as “plan,” “will,” “expect,” “anticipate,” “intend,” “believe,” “potential,” “continue,” and similar terms. These statements are subject to known or unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements, including but not limited to: challenges inherent in pharmaceutical research and development, including the timing and results of preclinical and clinical programs, where the risk of failure is high and failure can occur at any stage prior to or after regulatory approval due to lack of sufficient efficacy, safety considerations, or other factors; our ability to leverage and enhance our drug discovery platform; our ability to obtain financing for development activities and other corporate purposes; the success of our collaboration activities; our ability to obtain regulatory approval of, and ultimately commercialize, drug candidates; our ability to obtain, maintain, and enforce intellectual property protections; cyberattacks or other disruptions to our technology systems; our ability to attract, motivate, and retain key employees and manage our growth; inflation and other macroeconomic issues; and other risks and uncertainties such as those described under the heading “Risk Factors” in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K. All forward-looking statements are based on management’s current estimates, projections, and assumptions, and Recursion undertakes no obligation to correct or update any such statements, whether as a result of new information, future developments, or otherwise, except to the extent required by applicable law.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/21f011ab-bada-4c3e-a55f-d8eabecf35ad

GlobeNewswire Distribution ID 9090097